Endpoints News
Daiichi Sankyo's triple-negative breast cancer approval Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
M T W Th Fri
22 May, 2026
ENDPOINTS at #ASCO26
ASCO is about to deliver some make-or-break cancer data. Join us to figure out which pipeline bets will pay off. Get your spot now.
top stories
1. Novartis says Avidity's science could apply beyond muscular dystrophies
2. FDA grants Daiichi Sankyo and AstraZeneca’s Datroway a key breast cancer approval
3.
news briefing
Tender offer for Recordati; Sobi's gout drug passes Phase 3 test
4. Biogen, Denali to drop drug in non-genetic Parkinson’s after mid-stage study flop
5. Ibrance's would-be successors, the data that helped sell Tubulis to Gilead, and more at ASCO
6.
peer review
Amgen CFO to follow David Reese into retirement; Josh Smiley is out at Zai Lab
7. Exclusive: Inside the covert campaign to push out FDA Commissioner Marty Makary
8.
in focus
Fetal gene therapy inches closer. Will embryo editing follow?
9. Q&A: Novo Nordisk research chief discusses streamlined R&D, asset integration and role of AI
more stories
• 
• 
• 
• 
Alex Hoffman
.

In case you’re having a slow day, it’s a good time to register for Endpoints at #ASCO26, as we break down a big year of cancer data. Register here for the June 3 event.

We’ll be off Monday, as we hope you will be. So enjoy the long weekend (despite the lousy weather if you’re on the US East Coast)!
.
Alex Hoffman
Senior Copy Editor, Endpoints News
Vas Narasimhan, Novartis CEO (Chris J. Ratcliffe/Bloomberg via Getty Images)
1
by Ayisha Sharma

No­var­tis said it's work­ing to get the most out of its $12 bil­lion ac­qui­si­tion of Avid­i­ty Bio­sciences by find­ing ways to ap­ply its un­der­ly­ing sci­ence...

Read full story
AstraZeneca and Daiichi Sankyo at #ASCO25 (Max Gelman for Endpoints News)
2
by Lei Lei Wu

The FDA has ap­proved the TROP2-di­rect­ed an­ti­body-drug con­ju­gate Da­troway as a first-line op­tion for triple-neg­a­tive breast can­cer, giv­ing Dai­ichi Sankyo and As­traZeneca a leg up...

Read full story
LGBTQ+ LEADERSHIP IN 2026
LGBTQ+ diversity drives innovation in biopharma — but transgender and non-binary professionals face rising challenges. Endpoints is going live with our fourth annual special report celebrating the honorees giving voice and visibility while forging ahead across life sciences. Join us.
News Briefing: Quick hits from the biopharma web
3
by ENDPOINTS

Plus, news about Im­muno­vant and Retro Bio­sciences.

💸 CVC and GBL launch ten­der of­fer for Recor­dati: CVC Cap­i­tal Part­ners and Groupe Brux­elles Lam­bert (GBL), a...

Read full story
4
by Ayisha Sharma

Bio­gen and De­nali Ther­a­peu­tics’ LRRK2 in­hibitor has flunked a Phase 2b tri­al in ear­ly Parkin­son’s dis­ease, lead­ing the com­pa­nies to drop the pro­gram in cer­tain...

Read full story